FDA warns compounder; FDA updates drug communication policies;

> Another drug compounder has received a warning letter. Warning

> Pfizer ($PFE) and Protalix BioTherapeutics ($PLX) have won FDA approval for pediatric use of Elelyso for long-term enzyme replacement therapy for Type 1 Gaucher disease. Release

> The FDA has updated its policies on how it will communicate drug approval information. Report

> Patient-recruitment specialist Synexus has expanded its presence in South Africa, buying up another trial site in the country as it touts a growing list of clients. Story